Working to Eradicate Gynecologic Cancers

SS3
Sunrise Seminar III: Avoiding Clinical Catastrophes when Incorporating Novel Targeted Agents into Care of Gynecologic Cancer Patients

Sunday, March 29, 2015: 6:30 AM-7:30 AM
Grand Ballroom (Hilton Chicago)
Description: This seminar will dissect mechanisms of action, serious and common adverse events by type and frequency, and clinical complications that are seen when agents in the newer classes of targeted agents are used in the care of women with gynecologic cancers. Elements pertinent to safe surgical interventions, biopsy and subsequent treatment modalities will be considered. Novel agent classes to be discussed include anti-angiogenics, PARP inhibitors and MEK/AKT/mTOR inhibitors.
Course Directors:  Elise C. Kohn, MD, National Cancer Institute, Bethesda, MD and Robert Allen Burger, MD, University of Pennsylvania, Philadelphia, PA
Faculty:  Leslie M. Randall, MD, University of California at Irvine Medical Center, Orange, CA, Jung-min Lee, MD, National Cancer Institute, Bethesda, MD and Joyce F. Liu, MD, MPH, Dana-Farber Cancer Institute, Boston, MA
6:30 AM
Introductory Remarks for Avoiding Clinical Catastrophes
E. C. Kohn1 and R. A. Burger2
1National Cancer Institute, Bethesda, MD, 2University of Pennsylvania, Philadelphia, PA
 
6:35 AM
Crisis aversion and disaster management for anti-angiogenic therapy
L. M. Randall
University of California at Irvine Medical Center, Orange, CA
 
6:55 AM
PARP inhibitors
J. M. Lee
National Cancer Institute, Bethesda, MD
 
7:10 AM
Clinical considerations and toxicities with PI3K pathway and MEK inhibitors
J. F. Liu
Dana-Farber Cancer Institute, Boston, MA
 
7:25 AM
Discussion
 
See more of: Sunrise Seminar
<< Previous Course | Next Course >>